Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Maintaining Brain Sugar Levels May Be Key to Alzheimer’s Prevention

By BiotechDaily International staff writers
Posted on 13 Mar 2012
Preventing or slowing the development of Alzheimer’s disease (AD), a fatal brain disorder expected to impact one in 85 people worldwide by 2050, may be as easy as making sure a brain protein’s sugar levels are maintained.

This is the conclusion of seven researchers, including Dr. David Vocadlo, a Simon Fraser University (SFU; Burnaby, BC, Canada) chemistry professor and Canada research chair in chemical glycobiology, make in the March 2012 issue of Nature Chemical Biology. The journal has published the researchers’ latest paper Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation.

Dr. Vocadlo and his coworkers described how they have employed an inhibitor they have chemically created--Thiamet-G--to block O-GlcNAcase, a naturally occurring enzyme, from depleting the protein Tau of sugar molecules. “The general thinking in science,” said Dr. Vocadlo, “is that Tau stabilizes structures in the brain called microtubules. They are kind of like highways inside cells that allow cells to move things around.”

Previous research has demonstrated that the linkage of these sugar molecules to proteins, such as Tau, in cells is vital. In fact, according to Dr. Vocadlo, researchers have tried but failed to rear mice that do not have these sugar molecules attached to proteins.

Dr. Vocadlo, an accomplished chess player, is having great success checkmating problematic enzymes with inhibitors he and his students are creating in the SFU chemistry department’s laboratory of chemical glycobiology.

Earlier research to Dr. Vocadlo’s has revealed that clumps of Tau from an AD brain have nearly none of this sugar attached to them, and O-GlcNAcase is the enzyme that is robbing them. Such clumping is an early event in the development of AD and the amount of clumps correlate with the disease’s severity.

Scott Yuzwa and Xiaoyang Shan, grad students in Dr. Vocadlo’s lab, discovered that Thiamet-G blocks O-GlcNAcase from removing sugars off Tau in mice that drank water with a daily dose of the inhibitor. The researchers found that mice given the inhibitor had fewer clumps of Tau and maintained healthier brains.

“This work shows targeting the enzyme O-GlcNAcase with inhibitors is a new potential approach to treating Alzheimer’s,” said Dr. Vocadlo. “This is vital since to date there are no treatments to slow its progression. A lot of effort is needed to tackle this disease and different approaches should be pursued to maximize the chance of successfully fighting it. In the short term, we need to develop better inhibitors of the enzyme and test them in mice. Once we have better inhibitors, they can be clinically tested.”

Related Links:
Simon Fraser University



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Diagram illustrates the innovative process that could lead to more effective drugs against influenza infection (Photo courtesy of the Hebrew University of Jerusalem).

Researchers Show How the Influenza Virus Blocks Natural Killer Cell Recognition

A team of molecular virologists has described how the influenza virus evolved a defense mechanism to protect it from attack by the immune system's natural killer (NK) cells. The recognition of pathogen-infected... Read more

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

Genome-Wide Mutation-Searching Computational Software Designed for Genomic Medicine

Analysis software cross-references a patient’s symptoms with his genome sequence to help physicians in the diagnosis of disease. This software was created by a team of scientists from A*STAR’s Genome Institute of Singapore (GIS), led by Dr. Pauline Ng. The research findings were published August 3, 2014, in the journal... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.